Axsome Therapeutics, Inc. (FRA:19X)

Market Cap	7.86B +48.2%
Revenue (ttm)	478.36M +65.8%
Net Income	-195.63M
EPS	-3.97
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	156.95
Previous Close	155.05
Day's Range	156.95 - 156.95
52-Week Range	85.00 - 162.40
Beta	n/a
RSI	58.28
Earnings Date	Feb 23, 2026

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 816
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 19X

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial numbers in USD